Research
Hormonal
Obesity is a chronic, progressive, relapsing, multifactorial neurobehavioral disease driven by complex brain-gut-adipose interactions, not merely a lack of willpower.
Stop blaming yourself for your weight. Obesity is a biological disease involving hormones and brain signaling, not a character flaw. Seek medical care that treats the underlying biology, not just willpower.
StrongSupportsHIGH confidence
The Obesity Medicine Association (OMA) offers a more detailed perspective, describing obesity as a 'chronic, progressive, relapsing, multifactorial, neurobehavioral disease' that results from an increase in body fat.
Why this rating
The paper is a comprehensive review citing numerous high-quality studies and consensus statements.
Source
Obesity as a Disease: A Primer on Clinical and Physiological Insights
Aayush Shah et al. · Methodist DeBakey Cardiovascular Journal · 2025
DOI 10.14797/mdcvj.1515
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.Strong
- Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.Strong
- The Edmonton Obesity Staging System (EOSS) provides a more comprehensive clinical management framework than BMI alone by categorizing obesity based on health complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →